{"filing":{"accession_number":"0000885725-26-000049","cik":"0000885725","ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","form":"8-K","filing_date":"2026-07-27","report_date":"2026-07-21","primary_document":"bsx-20260721.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000049/bsx-20260721.htm"},"events":[{"id":20678,"run_id":18613,"accession_number":"0000885725-26-000049","anchor_item_number":"2.05","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Boston Scientific's Board approved the \"2026 Restructuring Plan\" on July 21, 2026, which explicitly includes \"headcount reductions\" and \"termination benefits\" as part of a multi-year restructuring. The filing discloses estimated total pre-tax charges of $700–$800 million, with termination benefits of $275–$300 million, supply chain optimization, and functional transformation activities. This is a classic workforce reduction and operational restructuring event under Item 2.05, material to investors assessing the company's cost structure and future profitability.","company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","filing_date":"2026-07-27","form":"8-K","submitted_at":null,"items":[{"id":20109,"accession_number":"0000885725-26-000049","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Boston Scientific's Board approved the \"2026 Restructuring Plan\" on July 21, 2026, which explicitly includes \"headcount reductions\" and \"termination benefits\" as part of a multi-year restructuring. The filing discloses estimated total pre-tax charges of $700–$800 million, with termination benefits of $275–$300 million, supply chain optimization, and functional transformation activities. This is a classic workforce reduction and operational restructuring event under Item 2.05, material to investors assessing the company's cost structure and future profitability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:12:44.826488+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20109,"accession_number":"0000885725-26-000049","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Boston Scientific's Board approved the \"2026 Restructuring Plan\" on July 21, 2026, which explicitly includes \"headcount reductions\" and \"termination benefits\" as part of a multi-year restructuring. The filing discloses estimated total pre-tax charges of $700–$800 million, with termination benefits of $275–$300 million, supply chain optimization, and functional transformation activities. This is a classic workforce reduction and operational restructuring event under Item 2.05, material to investors assessing the company's cost structure and future profitability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T20:12:44.826488+00:00","company_name":"BOSTON SCIENTIFIC CORP","ticker":"BSX","filing_date":"2026-07-27"}]}